ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2667

Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience

Elena Baldissera1, Alessandro Tomelleri 1, Corrado Campochiaro 2, Silvia Sartorelli 3 and Lorenzo Dagna 1, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, 2Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, 3Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Tocilizumab (TCZ) has recently been shown to be effective and safe for the treatment of patients with giant cell arteritis (GCA). Here we describe our real-life experience with TCZ in a large cohort of GCA patients from a single Italian Centre.

Methods: GCA patients, diagnosed according to the 1990 ACR criteria, followed-up at our Large Vessel Vasculitis Clinic and treated with TCZ were included. We retrospectively evaluated demographic features, disease characteristics, reasons for TCZ introduction and discontinuation, concomitant therapies and response to treatment. For each patient we also evaluated potential eligibility for GiACTA trial. For statistical comparisons non-parametric tests were used.

Results: 34 patients (28 women, mean age 71.3±10 years) were included. Table 1 summarizes GCA clinical features, tools for GCA diagnosis (imaging and/or biopsy), and reasons for TCZ introduction. Mean disease duration before TCZ introduction was 23±31.3 months. Only 11 patients met both GiACTA inclusion and exclusion criteria at TCZ introduction. 26 patients were followed up for 3 months, 22 for 6 months and 15 for 12 months. Mean prednisone (PDN) dose at TCZ introduction was 23.23±13.84 mg. Mean PDN dose was 8.41±7.10 mg (p < 0.001) at month 3, 4.95±5.63 mg (p = 0.02) at month 6, and 2.66±2.7 mg (p = 0.05) at month 12. PDN was stopped in 9 patients (2 at month 3, 5 at month 6, 2 at month 12) due to optimal disease control with TCZ alone. At TCZ introduction 4 patients were already on methotrexate (MTX). MTX was subsequently stopped in 2 patients (1 at month 3, 1 at month 6) due to disease control. TCZ was temporarily held off in 2 patients due to zoster reactivation and in 2 patients due to mild bacterial infections, and definitively stopped after 2 months (when PDN dose was still high) in 2 patients due to severe bacterial infections. No patient experienced severe neutropenia or liver enzymes elevation. In no case TCZ was judged inefficient.

Conclusion: Our data confirm TCZ is highly effective in GCA treatment and has a significant steroid-sparing effect. In our real-life retrospective study TCZ was also shown to be a safe option in patients with relapsing or refractory GCA.


Table 1 – TCZ in GCA

Clinical features, tools for diagnosis -imaging and/or biopsy-, and reasons for tocilizumab introduction in our cohort of patients with Giant Cell Arteritis.


Disclosure: E. Baldissera, Sobi, 8, Sanofi, 5, Roche, 8, Pfizer, 8, Novartis, 8, Abbvie, 8, Alfa-sigma, 8; A. Tomelleri, None; C. Campochiaro, GSK, 8, GSK, SOBI, Pfizer, 5, 8, Pfizer, 8, SOBI, 5; S. Sartorelli, None; L. Dagna, Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Sanofi-Genzyme, and SOBI., 5, 8.

To cite this abstract in AMA style:

Baldissera E, Tomelleri A, Campochiaro C, Sartorelli S, Dagna L. Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-giant-cell-arteritis-a-monocentric-real-life-experience/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-giant-cell-arteritis-a-monocentric-real-life-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.